Inventiva (IVA) Competitors $3.10 -0.20 (-6.06%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. VIR, NUVB, QURE, AVXL, IMNM, AVBP, TRVI, PHAR, DAWN, and DNTHShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Vir Biotechnology (VIR), Nuvation Bio (NUVB), uniQure (QURE), Anavex Life Sciences (AVXL), Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Vir Biotechnology Nuvation Bio uniQure Anavex Life Sciences Immunome ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Inventiva (NASDAQ:IVA) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings. Does the MarketBeat Community prefer IVA or VIR? Vir Biotechnology received 34 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 56.86% of users gave Vir Biotechnology an outperform vote. CompanyUnderperformOutperformInventivaOutperform Votes2482.76% Underperform Votes517.24%Vir BiotechnologyOutperform Votes5856.86% Underperform Votes4443.14% Which has better valuation & earnings, IVA or VIR? Inventiva has higher earnings, but lower revenue than Vir Biotechnology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.20M17.74-$119.51MN/AN/AVir Biotechnology$14.30M43.59-$615.06M-$4.22-1.07 Do analysts rate IVA or VIR? Inventiva presently has a consensus target price of $10.40, suggesting a potential upside of 234.41%. Vir Biotechnology has a consensus target price of $32.86, suggesting a potential upside of 628.54%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media refer more to IVA or VIR? In the previous week, Vir Biotechnology had 8 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Vir Biotechnology and 0 mentions for Inventiva. Vir Biotechnology's average media sentiment score of 1.31 beat Inventiva's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Inventiva Neutral Vir Biotechnology Positive Do insiders and institutionals have more ownership in IVA or VIR? 19.1% of Inventiva shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, IVA or VIR? Inventiva has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Is IVA or VIR more profitable? Inventiva has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Inventiva's return on equity of 0.00% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Vir Biotechnology -678.40%-36.71%-31.00% SummaryVir Biotechnology beats Inventiva on 10 of the 16 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.20M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales17.74250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book-4.646.466.794.50Net Income-$119.51M$143.98M$3.23B$248.18M7 Day Performance-11.14%3.04%4.07%1.14%1 Month Performance-12.64%7.44%12.52%15.20%1 Year Performance-19.22%-2.46%16.83%6.56% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva1.4902 of 5 stars$3.11-5.8%$10.40+234.4%-17.1%$163.20M$9.20M0.00100Gap DownVIRVir Biotechnology3.1079 of 5 stars$5.30+4.1%$32.86+519.9%-51.2%$731.74M$14.30M-1.35580Positive NewsNUVBNuvation Bio3.7294 of 5 stars$2.15+2.6%$7.83+265.2%-38.0%$726.47M$7.87M-0.9960News CoveragePositive NewsQUREuniQure2.9691 of 5 stars$13.15+2.8%$37.82+187.6%+215.7%$720.30M$27.12M-2.65500Analyst UpgradeOptions VolumeAnalyst RevisionAVXLAnavex Life Sciences3.7742 of 5 stars$8.55+3.6%$44.00+414.6%+70.0%$704.32MN/A-15.5540IMNMImmunome2.6231 of 5 stars$7.94+6.4%$25.33+219.1%-38.0%$690.88M$9.04M-0.9840Gap DownAVBPArriVent BioPharma1.0129 of 5 stars$19.99-0.8%$39.00+95.1%+6.5%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.6055 of 5 stars$6.70+1.5%$17.56+162.1%+128.6%$669.28MN/A-15.2320News CoveragePositive NewsAnalyst ForecastPHARPharming Group1.653 of 5 stars$9.81-2.2%$30.00+206.0%+11.5%$667.04M$297.20M-37.71280Negative NewsGap UpDAWNDay One Biopharmaceuticals2.9161 of 5 stars$6.58+2.0%$30.57+364.6%-58.8%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.2877 of 5 stars$20.08+2.5%$54.33+170.6%-24.9%$645.09M$6.24M-8.0380 Related Companies and Tools Related Companies VIR Competitors NUVB Competitors QURE Competitors AVXL Competitors IMNM Competitors AVBP Competitors TRVI Competitors PHAR Competitors DAWN Competitors DNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVA Stock Free IVA Stock Alerts